Hubs

The Investment Landscape Hub

Powered by G-FINDER, this hub is your go-to resource for data and analysis on the funding landscape for global health R&D. This is where you'll find all the G-FINDER reports across neglected disease, emerging infectious diseases and sexual & reproductive health.

Hub Editors

Dr Paul Barnsley

Research and Analysis Lead

Dr Sabastine Wakdok

Director of Research

Mapping the landscape

What is impacting global health?

Every year the G-FINDER project delivers the latest comprehensive data on global investment into R&D of new products to prevent, diagnose, control or cure diseases which kill millions. We analyse the funding landscape to show you where the money is coming from and where it's going. We reveal areas of growth, areas of decline and where we have gaps. We track which products have entered or moved along the pipeline thanks to this investment. This hub collates this huge resource of data and analysis in one place, where you can explore the findings and assess the implications.

The 2024 G-FINDER Neglected Disease R&D report

63%

of global funding came from governments in 2023

Which is a record low

83%

of global philanthropic investment in 2023

Is from the Gates Foundation

12%

of the global vaccine funding in 2023 is for TB

Up from 5% in 2018

Spotlight on latest reports

Relied on by governments, NGOs, private and philanthropic funders, product developers and global health advocates worldwide to inform decisions on R&D funding.

Is this the new era? Funding for sexual & reproductive health R&D 2018-2023

This is the fourth in a series of reports summarising the state of global funding for LMIC-applicable biomedical research and development targeting a range of sexual &...

Smart Decisions: The G-FINDER 2024 Neglected Disease R&D report

Tough choices in global health need people who will make smart decisions. This report provides strong data and solid insights to empower the community.

G-FINDER 2024 Landscape of Emerging Infectious Disease Research & Development report: Lessons Learned

This is our third report analysing global investment into research and development for emerging infectious diseases

Online webinar held 17 June 2025

Watch the recording of the report launch event where we reflect on the critical trends, gaps, and opportunities to shape the future of SRH and women's health innovation. Our guest speaker was Dr Nigina Muntean, Chief of the Innovation and Transformation Branch at UNFPA.

All resources in this hub

45 min read

A New Era? Funding for sexual & reproductive health R&D 2018-2023

This is the fourth in a series of reports summarising the state of global funding for LMIC-applicable biomedical research and development targeting a range of sexual & reproductive health and women’s health issues

Impact Global Health 30 Apr 2025

10 min read

In turbulent times, Europe must double down on its investments in Global Health R&D

Vanessa Candeais shows how investment in global public goods, global solidarity, and equity is a strategic necessity for Europe, providing clarity and leadership for the world and for its own future.

Vanessa Candeias10 Feb 2025

10 min read

Smart Decisions launch event notes

We share the summary notes and slides from the launch of the Smart Decisions: the G-FINDER 2024 Neglected Disease R&D report

Impact Global Health 5 Feb 2025

5 min read

Neglected disease funders

Who was funding what in 2023 and what does this mean for the future?

Impact Global Health 29 Jan 2025

5 min read

Discussion

Key messages from the 2023 global health R&D funding landscape and our recommendations for funders.

Impact Global Health 29 Jan 2025

5 min read

Introduction

Start here for the 2024 G-FINDER Neglected Disease R&D report - entitled Smart Decisions.

Impact Global Health 29 Jan 2025

5 min read

Funding by disease

How much R&D funding for which diseases did we see in 2023?

Impact Global Health 29 Jan 2025

10 min read

Enhancing global health policy-making with data: a look at G-FINDER and Compass

In this blog, our Chief Operating Officer, Anna Doubell, explains how we collect and curate the funding and pipeline data that drives decisions and informs policies in global health R&D.